Drugs / RO5545965
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02824055 | Jun 2016 → Apr 2017 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02019329 | Jan → Aug 2014 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01923025 | Aug → Nov 2013 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01864226 | Jun 2013 → Jan 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01711801 | Oct 2012 → Mar 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5545965 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01864226 ↗ |
| Route | Oral | “following oral administration” NCT01711801 ↗ |